Simulations Plus, Inc. (USD) Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.

Simulations Plus, Inc. (USD) Active

42505 Tenth Street West, Lancaster, CA, US, 93534-7059

Stock Price USD

Price Change

Last Dividend USD

B-

Latest Rating

SLP's stock peer is ACIU (AC Immune S.A.)

SLP's stock peer is AGL (Agilon Health, Inc.)

SLP's stock peer is ANRO (Alto Neuroscience, Inc.)

SLP's stock peer is CLLS (Cellectis S.A.)

SLP's stock peer is DH (Definitive Healthcare Corp.)

SLP's stock peer is KRRO (Korro Bio, Inc.)

SLP's stock peer is NAKA (Nakamoto Inc.)

SLP's stock peer is NRC (National Research Corporation)

SLP's stock peer is OPRX (OptimizeRx Corp.)

SLP's stock peer is SOPH (SOPHiA GENETICS S.A.)

Healthcare Medical - Healthcare Information Services

Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.

80%

Dcf Rating

20%

Return On Equity

20%

Return On Assets

80%

Debt To Equity

20%

Price To Earnings

60%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
2024-07-29	2024-08-05	0.06	0.60 %	Quarterly
2024-04-29	2024-05-06	0.06	0.54 %	Quarterly
2024-01-29	2024-02-05	0.06	0.62 %	Quarterly
2023-10-30	2023-11-06	0.06	0.71 %	Quarterly
2023-07-31	2023-08-07	0.06	0.49 %	Quarterly
2023-04-24	2023-05-01	0.06	0.56 %	Quarterly
2023-01-30	2023-02-06	0.06	0.61 %	Quarterly
2022-10-31	2022-11-07	0.06	0.56 %	Quarterly
2022-07-25	2022-08-01	0.06	0.40 %	Quarterly
2022-04-25	2022-05-02	0.06	0.50 %	Quarterly
2022-01-31	2022-02-07	0.06	0.59 %	Quarterly
2021-10-25	2021-11-01	0.06	0.61 %	Quarterly
2021-07-26	2021-08-02	0.06	0.51 %	Quarterly
2021-04-26	2021-05-03	0.06	0.35 %	Quarterly
2021-01-25	2021-02-01	0.06	0.32 %	Quarterly
2020-10-26	2020-11-02	0.06	0.34 %	Quarterly
2020-07-27	2020-08-03	0.06	0.36 %	Quarterly
2020-04-24	2020-05-01	0.06	0.57 %	Quarterly
2020-01-27	2020-02-03	0.06	0.71 %	Quarterly
2019-10-25	2019-11-01	0.06	0.72 %	Quarterly
2019-07-25	2019-08-01	0.06	0.66 %	Quarterly
2019-04-24	2019-05-01	0.06	1.09 %	Quarterly
2019-01-25	2019-02-01	0.06	1.25 %	Quarterly
2018-11-01	2018-11-08	0.06	1.19 %	Quarterly
2018-07-26	2018-08-02	0.06	1.27 %	Quarterly
2018-04-25	2018-05-02	0.06	1.31 %	Quarterly
2018-01-26	2018-02-02	0.06	1.37 %	Quarterly
2017-11-13	2017-11-20	0.06	1.27 %	Quarterly
2017-07-28	2017-08-04	0.05	1.27 %	Quarterly
2017-05-08	2017-05-15	0.05	1.58 %	Quarterly
2017-01-30	2017-02-06	0.05	2.03 %	Quarterly
2016-11-10	2016-11-17	0.05	2.29 %	Quarterly
2016-08-11	2016-08-18	0.05	2.42 %	Quarterly
2016-05-02	2016-05-09	0.05	2.44 %	Quarterly
2016-01-29	2016-02-05	0.05	1.94 %	Quarterly
2015-11-09	2015-11-16	0.05	2.25 %	Quarterly
2015-07-23	2015-07-30	0.05	2.97 %	Quarterly
2015-05-11	2015-05-18	0.05	3.39 %	Quarterly
2015-01-26	2015-02-02	0.05	3.05 %	Quarterly
2014-11-07	2014-11-14	0.05	3.12 %	Quarterly
2014-08-04	2014-08-11	0.05	3.18 %	Quarterly
2014-05-09	2014-05-16	0.05	2.82 %	Quarterly
2014-02-17	2014-02-24	0.05	2.56 %	Quarterly
2013-11-08	2013-11-15	0.04	4.44 %	Quarterly
2013-08-12	2013-08-15	0.03	5.21 %	Quarterly
2013-05-07	2013-05-10	0.03	6.75 %	Quarterly
2012-12-24	2012-12-28	0.14	6.70 %	Quarterly
2012-11-08	2012-11-13	0.05	4.31 %	Quarterly
2012-08-07	2012-08-10	0.05	3.61 %	Quarterly
2012-04-27	2012-05-08	0.05	2.27 %	Quarterly
2012-02-21	2012-03-01	0.05	1.20 %	Quarterly

Recent News

Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The investigation concerns whether Simulations Plus or certain of its officers and directors made false or misleading statements, or failed to disclose material information, concerning the Company's financial outlook, reporting practices, internal controls, and related accounting matters.

2026-06-26 11:04:00

Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel

SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The investigation concerns whether Simulations Plus or certain of its officers and directors made false or misleading statements, or failed to disclose material information, concerning the Company's financial outlook, reporting practices, internal controls, and related accounting matters. Simulations Plus Investors: Contact Johnson.

2026-06-24 12:04:00

Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that helps advance biopharma innovation, today announced it is building the agentic layer of Composer, its AI-native platform for model-informed drug development, using the NVIDIA BioNeMo Agent Toolkit. The initiative expands the companies' collaboration announced in May 2026, extending their work in GPU-.

2026-06-23 09:15:00

Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel

SAN DIEGO, June 22, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The investigation concerns whether Simulations Plus or certain of its officers and directors made false or misleading statements, or failed to disclose material information, concerning the Company's financial outlook, reporting practices, internal controls, and related accounting matters.

2026-06-22 11:44:00

Simulations Plus, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – SLP

LOS ANGELES--(BUSINESS WIRE)---- $SLP--Simulations Plus, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – SLP.

2026-06-18 16:29:00

Simulations Plus Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Simulations Plus, Inc. - SLP

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Simulations Plus, Inc. (NasdaqGS: SLP) to affiliates of Altaris, LLC. Under the terms of the proposed transaction, shareholders of Simulations will receive $18.50 in cash for each share of Simulations that they own. KSF is seeking to determine whether this consideration and the process that led.

2026-06-18 16:08:00

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Simulations Plus, Inc. (NASDAQ: SLP)

NEW YORK, June 18, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Simulations Plus, Inc. (NASDAQ: SLP ) related to its sale to affiliates of Altaris, LLC.

2026-06-18 13:42:00

Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel

SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The investigation concerns whether Simulations Plus or certain of its officers and directors made false or misleading statements, or failed to disclose material information, concerning the Company's financial outlook, reporting practices, internal controls, and related accounting matters.

2026-06-17 12:04:00

SLP Investors Have Opportunity to Join Simulations Plus, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $SLP--SLP Investors Have Opportunity to Join Simulations Plus, Inc. Fraud Investigation with the Schall Law Firm.

2026-06-16 17:31:00

Shareholder Alert: Ademi LLP investigates whether Simulations Plus, Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE, June 16, 2026 /PRNewswire/ -- Ademi LLP is investigating Simulations Plus (NASDAQ: SLP) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Altaris. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

2026-06-16 13:36:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions